Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1>
PARP-2> PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication …

Simple Summary This review aims to analyze the emerging issue regarding PARP inhibitor's
resistance in tumors and their consequence on disease prognosis and treatment. Besides …

Abstract PARP (poly (ADP-ribose) polymerase) inhibitors represent a novel class of anti-
cancer therapy; they take advantage of synthetic lethality and induce cell death by exploiting …

Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …

Homologous recombination (HR) repair deficiency impairs the proper maintenance of
genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair …

PARP inhibitors (PARPi), a cancer therapy targeting poly (ADP-ribose) polymerase, are the
first clinically approved drugs designed to exploit synthetic lethality, a genetic concept …

Editorial summary Inhibitors of poly (ADP-ribose) polymerase (PARPi) have entered the
clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but …

Personalized medicine seeks to utilize targeted therapies with increased selectivity and
efficacy in preselected patient cohorts. One such molecularly targeted therapy is enabled by …